How is leflunomide prescribed and used in Australia? Analysis of prescribing and adverse effect reporting

Pharmacoepidemiology and Drug Safety

Volumn 15, Issue 7, 2006, Pages 485-493

  Chan, Vivien ^a   Tett, Susan E ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Adverse drug reactions; Defined daily dose; Drug utilization; Leflunomide

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; LEFLUNOMIDE; METHOTREXATE;

APPLICATION SITE REACTION; ARTICLE; AUSTRALIA; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; COLLAGEN DISEASE; COMMUNITY; DATA BASE; DRUG APPROVAL; DRUG FATALITY; DRUG MEGADOSE; DRUG SURVEILLANCE PROGRAM; DRUG USE; DRUG UTILIZATION; ENDOCRINE DISEASE; ERYTHROCYTE DISORDER; FETUS DISEASE; GASTROINTESTINAL DISEASE; GYNECOLOGIC DISEASE; HEARING DISORDER; HEART ARRHYTHMIA; HEMATOLOGIC DISEASE; HEPATOBILIARY DISEASE; HUMAN; INFANT DISEASE; LEUKOCYTE DISORDER; LOW DRUG DOSE; MENTAL DISEASE; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NEOPLASM; NEUROTOXICITY; NEWBORN DISEASE; NUTRITIONAL DISORDER; PERIPHERAL NEUROPATHY; PRESCRIPTION; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RHEUMATOLOGY; SENSORY DYSFUNCTION; SKIN APPENDAGE DISEASE; SKIN MANIFESTATION; STATISTICAL ANALYSIS; TABLET; THROMBOCYTE DISORDER; URINARY TRACT DISEASE; VASCULAR DISEASE; VESTIBULAR DISORDER; VISUAL DISORDER; WORLD HEALTH ORGANIZATION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AUSTRALIA; DRUG PRESCRIPTIONS; HUMANS; ISOXAZOLES; PRESCRIPTIONS, DRUG;

EID: 33746656196     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1252     Document Type: Article

References (37)

1. Osiri M, Shea B, Robinson V, et al. Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2003; 30: 1182-1190.
2. Blomqvist P, Feltelius N, Ekbom A, Klareskog L. Rheumatoid arthritis in Sweden. Drug prescriptions, costs, and adverse drug reactions. J Rheumatol 2000; 27: 1171-1177.
3. Dougados M, Emery P, Lemmel EM, et al. Efficacy and safety of leflunomide and predisposing factors for treatment response in patients with active rheumatoid arthritis: RELIEF 6-month data. J Rheumatol 2003; 30: 2572-2579.
4. Conaghan PG, Crotty M, Oh E, Day RO, Brooks PM. Antirheumatic drug-prescribing behaviour of Australasian rheumatologists 1984-1994. Br J Rheumatol 1997; 36: 487-490.
5. Horsfall MWJ, Shaw JP, Highton J, Cranch PJ. Changing patterns in the use of slow acting antirheumatic drugs for the treatment of rheumatoid arthritis. N Z Med J 1998; 111: 200-203.
6. Ward MM. Trends in the use of disease modifying antirheumatic medications in rheumatoid arthritis, 1980-1995: results from the National Ambulatory Medical Care Surveys. J Rheumatol 1999; 26: 546-550.
7. Osiri M, Akkasilpa S, Deesomchok U. Initial disease modifying antirheumatic drugs and prednisolone prescriptions for patients with rheumatoid arthritis: a 15-year study. J Med Assoc Thai 2000; 83: 217-224.
8. Zink A, Listing J, Niewerth M, Zeidler H. The national database of the German Collaborative Arthritis Centres: II. Treatment of patients with rheumatoid arthritis. Ann Rheum Dis 2001; 60: 207-213.
9. Pope JE, Hong P, Koehler BE. Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: a survey of practicing Canadian rheumatologists. J Rheumatol 2002; 29: 255-260.
10. Aletaha D, Smolen JS. The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD courses. Rheumatology (Oxford) 2002; 41: 1367-1374.
11. Gonzalez-Alvaro I, Carmona L, Balsa A, Sanmarti R, Belmonte MA, Tena X. Patterns of disease modifying antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis. J Rheumatol 2003; 30: 697-704.
12. Maravic M, Bergé C, Daurès JP, Boissier MC. Survey of practices regarding management of early rheumatoid arthritis by rheumatologists in France. Clin Exp Rheumatol 2004; 22: 319-327.
13. Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999; 159: 2542-2550.
14. Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999; 353: 259-266.
15. Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000; 39: 655-665.
16. Australia Commonwealth Department of Health and Aged Care. Schedule of Pharmaceutical Benefits for approved pharmacists and medical practitioners: 1 February 2000. Canberra: AusInfo, 2000.
17. Health Insurance Commission. Pharmaceutical Benefits Schedule item statistics. URL: http://www.hic.gov.au/statistics/dyn_pbs/forms/ pbs_tab1.shtml (accessed 9 Feb 2005).
18. World Health Organisation Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment: Oslo 2002. 5th edn. Oslo: WHO Collaborating Centre for Drug Statistics Methodology, 2002.
19. Australian Bureau of Statistics. Australian Demographic Statistics Quarterly 2000-2002. Canberra: Australian Bureau of Statistics; ABS Catalogue no. 3101.0.
20. World Health Organisation Collaborating Centre for Drug Statistics Methodology. ATC index with DDDs 2002. Oslo: WHO Collaborating Centre for Drug Statistics Methodology, 2002.
21. Therapeutic Goods Administration. Adverse Drug Reactions Advisory Committee (ADRAC). URL: http://www.tga.gov.au/adr/adrac.htm (accessed 9 Feb 2005).
22. WHO Collaborating Centre for International Drug Monitoring. The Uppsala Monitoring Centre. URL: http://www.who-umc.org (accessed 9 Feb 2005).
23. WHO Collaborating Centre for International Drug Monitoring. The UMC Products & Services: Vigibase services. URL: http://www.umc-products.com/DynPage.aspx?id=4912 (accessed 9 Feb 2005).
24. Abdel-Nasser AM, Rasker JJ, Valkenburg HA. Epidemiological and clinical aspects relating to the variability of rheumatoid arthritis. Semin Arthritis Rheum 1997; 27: 123-140.
25. Australian Institute of Health and Welfare. Australia's Health 2004: the ninth biennial health report of the Australian Institute of Health and Welfare (AIHW catalogue no. AUS 44). URL: http://www.aihw.gov.au/ publications/index.cfm/title/10014 [accessed 2 August 2004].
26. Kremer JM, Genovese MC, Cannon GW, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002; 137: 726-733.
27. Jobanputra P, Wilson J, Douglas K, Burls A. A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis. Rheumatology (Oxford) 2004; 43: 206-210.
28. Rafferty T, McGavock H, Wilson-Davis K. Temporal trends in drug use in one UK region, revealed by chemical group matching. Pharmacoepidemiol Drug Safe 1997; 6: 93-100.
29. Therapeutic Goods Administration. Australian adverse drug reactions bulletin. URL: http://www.tga.gov.au/adr/aadrb.htm (accessed 9 Feb 2005). [Volume 20 (2) June 2001 and Volume 19 (1) February 2000 particularly relevant to leflunomide]
30. Maddison P, Kiely P, Kirkham B, et al. Leflunomide in rheumatoid arthritis: recommendations through a process of consensus. Rheumatology (Oxford) 2005; 44: 280-286.
31. Siva C, Eisen SA, Shepherd R, et al. Leflunomide use during the first 33 months after food and drug administration approval: experience with a national cohort of 3325 patients. Arthritis Rheum 2003; 49: 745-751.
32. Van Roon EN, Jansen TLTA, Mourad L, et al. Leflunomide in active rheumatoid arthritis: a prospective study in daily practice. Br J Clin Pharmacol 2004; 57: 790-797.
33. Verschueren P, Vandooren A, Westhovens R. Debilitating diarrhoea and weight loss due to colitis in two RA patients treated with leflunomide. Clin Rheumatol 2005; 24: 87-90.
34. Koo LC, Clark JA, Quesenberry CP, et al. National differences in reporting 'pneumonia' and 'pneumonia interstitial': an analysis of the WHO International Drug Monitoring Database on 15 drugs in nine countries for seven pulmonary conditions. Pharmacoepidemiol Drug Safe 2005; 14: 775-787.
35. Adverse Drug Reactions Advisory Committee (ADRAC). Leflunomide - serious hepatic, blood, skin and respiratory reactions. Australian Adverse Drug Reactions Bulletin 2001; 20: 7.
36. Chan J, Sanders DC, Du L, Pillans PI. Leflunomide-associated pancytopenia with or without methotrexate. Ann Pharmacother 2004; 38: 1206-1211.
37. Moride Y, Haramburu F, Requejo AA, Begaud B. Under-reporting of adverse drug reactions in general practice. Br J Clin Pharmacol 1997; 43: 177-181.